Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit
08/01/2022 - 08:00 AM
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Jim Thorburn , CFO of Twist Bioscience , and Patrick Finn , Ph.D., CCO of Twist Bioscience , will host a fireside chat and one-on-one meetings at the UBS Genomics 2.0 and Medtech Innovations Summit on Tuesday, August 9 th , at 2:00 p.m. Pacific Time in Dana Point, California .
The presentation will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here . A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
View source version on businesswire.com : https://www.businesswire.com/news/home/20220801005103/en/
Angela Bitting
SVP, Corporate Affairs
925-202-6211
media@twistbioscience.com
Source: Twist Bioscience Corporation
TWST Rankings
#4771 Ranked by Stock Gains
TWST Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
Country
US
City
South San Francisco
About TWST
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .